Belgian Byteflies and global biopharmaceutical company UCB are continuing their long-standing collaboration to improve the management of severe epilepsy through the TETRIS clinical study, which focuses on the potential of remote, multimodal patient monitoring.
The study is evaluating how continuous, home-based monitoring can provide physicians with the insights needed to make more informed and timely decisions during medication titration. For many people living with severe epilepsy, seizures occur at home, overnight and during everyday life rather than during scheduled hospital or clinic appointments.
The partners believe that capturing objective, continuous data in patients’ normal environments could help clinicians gain a more complete picture of disease activity and treatment response. The collaboration with UCB has evolved over almost a decade, shifting from early discussions around technology feasibility to developing practical use cases centred on patient value.
The company’s wearable monitoring technology is entirely non-invasive, making it particularly suitable for patients who struggle to tolerate conventional monitoring methods.
By collecting continuous physiological data safely in the home, Byteflies aims to support proactive disease management while helping to preserve patients’ quality of life.
The partnership has already contributed to several advances, including scientific validation of the technology, the development of an integrated digital health solution, and improved visibility of seizure patterns between clinical visits.
It also seeks to reduce reliance on patient memory and paper seizure diaries, enable home monitoring instead of hospital-based observation, and generate richer, more comprehensive data for rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome.
Ultimately, the goal is to support more personalised treatment optimisation through continuous, real-world data.
“Healthcare innovation is a marathon, not a sprint,” Byteflies said, describing its partnership with UCB as instrumental in bringing home-based epilepsy care to the forefront.
As the TETRIS clinical study progresses, the partners say they will continue to build on real-world insights to better understand epilepsy beyond the clinic and support more informed, targeted and proactive care for people living with the condition.
